Starr Insurance Receives License to Operate Branch in Seoul

NEW YORK--(BUSINESS WIRE)-- Starr Insurance announced that South Korea’s Financial Services Commission has granted Starr International Insurance (Singapore) Pte. Ltd., Korea branch, a license to operate in Seoul and begin selling commercial property/casualty insurance throughout Korea.

Paul Choi was named CEO of Starr’s Korea branch in May 2024. He has more than 30 years of insurance experience with brokers and carriers and holds an MS in Risk Management & Insurance from Georgia State University.

Phil Finley, president of Starr Asia Pacific, said: “Korea is one of the largest commercial insurance markets in Asia, and Starr has a long history of operating in the region. We expect Korea to become a good source of profitable premium growth for Starr over the coming years.”

About Starr Insurance

Starr Insurance (or Starr) is a marketing name for the operating insurance and travel assistance companies and subsidiaries of Starr International Company, Inc. and for the investment business of C. V. Starr & Co., Inc. and its subsidiaries. Starr is a leading insurance and investment organization with a presence on six continents; through its operating insurance companies, Starr provides property, casualty, and accident and health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance. Starr’s insurance company subsidiaries domiciled in the U.S., Bermuda, China, Hong Kong, Malta, Singapore, Switzerland and U.K. each have an A.M. Best rating of “A” (Excellent). Starr’s Lloyd’s syndicate has a Standard & Poor’s rating of “A+” (Strong).

Visit us at www.starrcompanies.com or follow us LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241020474942/en/

Charlie Armstrong
Vice President, Marketing
[email protected], 646.758.8308

Source: Starr Insurance

You May Also Be Interested In

• Exclusive Networks and ServiceNow Partner to Advance AI-Powered Cybersecurity Adoption Across EMEA
• Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
• Eurofins Makes Significant Progress in H1 2026 Towards Its Mid-Term 2027 Objectives, With 130bps of Adjusted EBITDA Margin Expansion, Strong Cash Conversion, and 29% EPS Growth